Cover Image
Market Research Report

Keloid Treatment Market: By Product (Elastic Wraps, Sprays, Ointment, Creams, Oils, & Topical Gels & Gel Sheets), By Treatment (Radiation, Cry, Surgical, Laser, Steroid Injections, & Interferon), & By Region-Forecast 2019-2024

Published by IndustryARC Product code 422057
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Keloid Treatment Market: By Product (Elastic Wraps, Sprays, Ointment, Creams, Oils, & Topical Gels & Gel Sheets), By Treatment (Radiation, Cry, Surgical, Laser, Steroid Injections, & Interferon), & By Region-Forecast 2019-2024
Published: December 26, 2018 Content info:
Description

Keloid scars are heap-up scars which are developed with injuries causing due to, acne, burns, ear piercing, chickenpox, surgical cuts, scratches and vaccination sites and build up abruptly on the skin surface. Keloid scars develop commonly in people between age group 10 to 20 years of age. Globally, development of advance technology based treatment, rise in the appearance consciousness, and increasing awareness about scare treatment products, and expenditure on personal care, and changing lifestyle are the prime growth drivers of global keloid treatment market. In addition, increase in adoption of of radiation therapy, surgical intervention, and steroid injections and, emerging economies such as China, India and others, will create new opportunities for global keloid treatment market. However, higher cost of treatment, and risk of side effects and complications during treatment are the key restraints for global keloid treatment market.

This report identifies the global keloid treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global keloid treatment market.

Geographically North America dominated global keloid treatment market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, growing disposable income, rising focus on personal well-being and modernizing healthcare infrastructure in this region. Among all the treatments, surgical treatment segment has the highest market share in global keloid treatment market.

This report segments global keloid treatment market on the basis of product, treatment, and regional market as follows:

Keloid Treatment Market, By Product: Elastic Wraps, Sprays, Ointment, Creams, Oils, and Topical Gels & Gel Sheets

The report has focused study on keloid treatment market by basis of treatment such as: Radiation Therapy, Cry Therapy, Surgical Treatment, Laser Treatment, Steroid Injections, and Interferon

This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the keloid treatment market. Some of the major companies' profiles in detail are as follows:

Bristol-Myers Squibb Company

Valeant Pharmaceuticals International Inc.

Renovo Group Plc

Galena Biopharma, Inc.

Pacific World Corporation

Table of Contents

Table of Contents

1. Keloid Treatment Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Keloid Treatment Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Development of advance technology based treatment
    • 4.1.2. Rise in the appearance consciousness
    • 4.1.3. Increasing awareness about scare treatment products, and expenditure on personal care, and changing lifestyle
  • 4.2. Restraints
    • 4.2.1. Higher cost of treatment
    • 4.2.2. Risk of side effects and complications during treatment
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
    • 4.3.2. Increase in adoption of radiation therapy, surgical intervention, and steroid injections for keloid treatment
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Keloid Treatment Market, By Product

  • 5.1. Elastic Wraps
  • 5.2. Sprays
  • 5.3. Ointment
  • 5.4. Creams
  • 5.5. Oils
  • 5.6. Topical Gels & Gel Sheets

6. Keloid Treatment Market, By Treatment

  • 6.1. Radiation Therapy
  • 6.2. Cry Therapy
  • 6.3. Surgical Treatment
  • 6.4. Laser Treatment
  • 6.5. Steroid Injections
  • 6.6. Interferon

7. Keloid Treatment Market, By Geography

  • 7.1. Europe
    • 7.1.1. Germany
    • 7.1.2. France
    • 7.1.3. Italy
    • 7.1.4. Spain
    • 7.1.5. Russia
    • 7.1.6. U.K.
    • 7.1.7. Rest of Europe
  • 7.2. Asia Pacific
    • 7.2.1. China
    • 7.2.2. India
    • 7.2.3. Japan
    • 7.2.4. South Korea
    • 7.2.5. Rest of Asia-Pacific
  • 7.3. North America
    • 7.3.1. U.S.
    • 7.3.2. Canada
    • 7.3.3. Mexico
  • 7.4. Rest of the World (RoW)
    • 7.4.1. Brazil
    • 7.4.2. Rest of RoW

8. Keloid Treatment - Market Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply- Contract

9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 9.1. Bristol-Myers Squibb Company
  • 9.2. Valeant Pharmaceuticals International Inc.
  • 9.3. Renovo Group Plc
  • 9.4. Galena Biopharma, Inc.
  • 9.5. Pacific World Corporation
  • 9.6. Rxi Pharmaceuticals, Inc.
  • 9.7. Novartis AG
  • 9.8. GlaxoSmithKline plc
  • 9.9. Revitol Corporation Inc.
  • 9.10. Avita Medical Limited

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

  • 10.1. Abbreviations
  • 10.2. Sources
  • 10.3. Research Methodology
  • 10.4. Expert Insights
Back to Top